Successful treatment of protein-losing enteropathy due to AA amyloidosis with octreotide in a patient with rheumatoid arthritis

REFERENCES

• Umar SB, DiBaise JK. Protein-losing enteropathy: case illustra-tions and clinical review. Am J Gastroenterol. 2010;105:43-9 (quiz 50).
   Google Scholar
• Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amy-loidosis, successfully treated with corticosteroid and octreotide. Amyloid. 2005;12:48–53.
   PubMed Web of Science ®Google Scholar
• Mei:lini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349: 583–96.
   Google Scholar
• Khan MF, Falk RH. Amyloidosis. Postgrad Med J. 2001;77: 686–93.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Amyloid A. Amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clin Exp Rheumatol. 2011;29:850–7.
   PubMed Web of Science ®Google Scholar
• Ishii W, Kishida D, Suzuki A, et al. A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept. Rheumatol Int. 2011;31:247–50.
   PubMed Web of Science ®Google Scholar
• Narvaez J, Hernandez MV, Ruiz JM, Vaquero CG, Juanola X, Nollaa JM. Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis. Joint Bone Spine. 2011;78:101–3.
   PubMed Web of Science ®Google Scholar
• Lee HL, Han DS, Kim JB, Jeon YC, Sohn JH, Hahm JS. Suc-cessful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report. J Korean Med Sci. 2004;19:466–9.
   PubMed Web of Science ®Google Scholar
• Yam LT, Oropilla SB. Octreotide for diarrhea in amyloidosis. Ann Intern Med. 1991;115:577.
   PubMed Web of Science ®Google Scholar
• Jeong YS, Jun JB, Kim TH, et al. Successful treatment of protein-losing enteropathy due to AA amyloidosis with somatostatin analogue and high dose steroid in ankylosing spondylitis. Clin Exp Rheumatol. 2000;18:619–21.
   PubMed Web of Science ®Google Scholar
• Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol. 2001;13:67–73.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–9.
   Google Scholar
• Gomez-Casanovas E, Sanmarti R, Sole M, Canete JD, Munoz-Gomez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001;44:66–72.
   Google Scholar
• Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Sus-ceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009;61:1435–40.
   PubMed Web of Science ®Google Scholar
• Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prev-alence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol. 2003;30:948–51.
   Google Scholar
• Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid. 2008;15:262–8.
   Google Scholar
• Okuda Y, Takasugi K, Oyama T, Onuma M, Oyama H. Amy-loidosis in rheumatoid arthritis-clinical study of 124 histologi-cally proven cases. Ryumachi. 1994;34: 939–46.
   Google Scholar
• Ebert EC, Nagar M. Gastrointestinal manifestations of amyloi-dosis. Am J Gastroenterol. 2008;103:776–87.
   PubMed Web of Science ®Google Scholar
• Suzuki C, Higaki S, Nishiaki M, et al. 99mTc-HSA-D scintig-raphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. J Gastroenterol. 1997;32:78–82.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Takasugi K, Oyama T, Oyama H, Nanba S, Miyamoto T. Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis. 1997;56:535–41.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Otaki Y, Sato H, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with inf-liximab. Rheumatol Int. 2008;28:1155–9.
   PubMed Web of Science ®Google Scholar
• Yazici Y, Erkan D, Levine DM, Parker TS, Lockshin MD. Pro-tein-losing enteropathy in systemic lupus erythematosus: report of a severe, persistent case and review of pathophysiology. Lupus. 2002;11:119–23.
   Google Scholar
• Bhattacharya S, Vijayasekar C, Worlding J, Mathew G. Octreo-tide in chemotherapy induced diarrhoea in colorectal cancer: a review article. Acta Gastroenterol Belg. 2009;72:289–95.
   PubMed Web of Science ®Google Scholar
• Szilagyi A, Shrier I. Systematic review: the use of somatostatin or octreotide in refractory diarrhoea. Aliment Pharmacol Ther. 2001;15:1889–97.
   PubMed Web of Science ®Google Scholar
• Kubba AK, Dallal H, Haydon GH, Hayes PC, Palmer KR. The effect of octreotide on gastroduodenal blood flow measured by laser Doppler flowmetry in rabbits and man. Am J Gastroenterol. 1999;94:1077–82.
   Google Scholar
• Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW, Schonbrunn A. Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J Clin Endocrinol Metab. 1999;84:2942–50.
   PubMed Web of Science ®Google Scholar
• Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol. 1999;29:2454–63.
   PubMed Web of Science ®Google Scholar
• Karalis K, Mastorakos G, Sano H, Wilder RL, Chrousos GP. Somatostatin may participate in the antiinflammatory actions of glucocorticoids. Endocrinology. 1995;136:4133–8.
   Google Scholar
• Paran D, Elkayam 0, Mayo A, et al. A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. Ann Rheum Dis. 2001;60:888–91.
   Google Scholar
• Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine. 2002;69:538–45.
   PubMed Web of Science ®Google Scholar